In the 5/6 nephrectomy rat model of chronic kidney disease in which diabetes does not feature, SGLT2 inhibition with empagliflozin ameliorated glomerular hypertrophy, glomerulosclerosis and interstitial fibrosis as effectively as inhibition of the renin angiotensin system with telmisartan (43). The gene discussed is SLC5A2; the disease is diabetes mellitus.